导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.55% | 2563/4773 |
| 近一周 | -0.92% | 1395/5465 |
| 近一月 | -8.25% | 4862/5421 |
| 近一季 | 13.67% | 131/5231 |
| 近半年 | 1.37% | 1171/4920 |
| 近一年 | -13.01% | 3593/4394 |
| 近两年 | 27.32% | 2402/2954 |
| 近三年 | -2.66% | 1968/2253 |
| 成立以来 | 32.39% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.95% 2029/4961 |
-3.61% 3466/5312 |
- - |
- - |
| 2025 | 11.00% 2770/4813 |
2.69% 1292/3635 |
2.70% 1419/4076 |
20.34% 1992/4524 |
-12.54% 4260/4813 |
| 2024 | -12.38% 2375/3463 |
-12.88% 2470/2808 |
-9.36% 2353/3014 |
20.68% 681/3129 |
-8.06% 2828/3463 |
| 2023 | -10.38% 1300/2656 |
-0.77% 1826/2280 |
-7.75% 1902/2385 |
0.42% 368/2515 |
-2.51% 482/2655 |
| 2022 | -23.98% 1180/2207 |
-11.40% 508/1919 |
-2.48% 1778/2016 |
-19.97% 1825/2113 |
9.94% 189/2208 |
| 2021 | -13.49% 1136/1822 |
-3.20% 781/1255 |
9.10% 585/1330 |
-14.13% 1363/1466 |
-4.60% 1490/1822 |
| 2020 | 51.18% 160/1250 |
6.37% 42/1028 |
31.10% 42/1067 |
3.61% 975/1164 |
4.63% 834/1184 |
| 2019 | 31.96% 453/1092 |
29.02% 286/754 |
-8.15% 580/804 |
6.25% 131/850 |
4.81% 777/918 |
| 2018 | -25.64% 359/834 |
- - |
- - |
- - |
-20.15% 667/691 |
| 2017 | 20.59% 182/714 |
- - |
- - |
- - |
- - |
| 2016 | -10.71% 286/605 |
- - |
- - |
- - |
- - |
| 2015 | 40.63% 42/575 |
- - |
- - |
- - |
- - |
| 2014 | 5.28% 224/237 |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华安中证细分医药ETF VS. 长安沪深300非周期A(740101) |